Table 2.
Antiviral activities of hyperoside (Hyp) in experimental models related to hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
| Hyperoside/Source | Experimental Model | Dose | Results/Molecular Mechanisms | References |
|---|---|---|---|---|
| Hyp/Abelmoschus manihot | HepG2.2.15 cells | 0.0125, 0.025, 0.05 g/L | ↓HBsAg ↓HBeAg |
[54] |
| Hyp/Abelmoschus manihot | Ducklings inoculated with duck HBV DNA | 0.1 g/kg/day | ↓serum HBV DNA | [54] |
| Hyp | Duck HBV infection model and normal mouse spleen lymphocyte | 25, 50 mg/kg | ↓serum HBV DNA ↓hepatic cccDNA ↓Th1 cytokine in normal mouse spleen lymphocyte |
[66] |
| Hyp | Ducklings inoculated with duck HBV DNA | 300 mg/kg | ↓serum HBV DNA ↓rebound of serum HBV DNA compared with lamivudine |
[67] |
| Hyp | Huh-7 cells transfected with NS3 gene of HCV | Not known | ↓HCV NS3 protease by docking the binding sites of NS3 protein | [69] |
HBV, hepatitis B virus; HCV, hepatitis C virus; NS3, nonstructural protein. Upward pointing arrow (↑) and downward pointing arrow (↓) represent an increase and a decrease in gene/protein expression or numerical values, respectively.